Application of ulinastatin in severe craniocerebral injuries.

Objective: To assess the therapeutic effect of ulinastatin on severe craniocerebral injuries and to explore its mechanism.

Methods: There were 87 cases of severe brain injury in this series and they were either treated by ulinastatin (treatment group, 41 cases) or not (control group, 46 cases) besides routine managements. We estimated C-reactive protein, interleukin-6, superoxide dismutase, and endothelin from plasmas of all the cases on the 1st, 3rd, 5th, and 7th day after injury.